Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
Key claim: This trial directly compares momelotinib versus ruxolitinib as first-line treatments for myelofibrosis patients with low blood cell counts, with spleen volume reduction as the primary endpoint.
Abstract
The purpose of this study is to compare momelotinib and ruxolitinib as treatments for myelofibrosis with low blood cell counts. Both drugs are approved by the FDA to treat myelofibrosis. The study asks which drug does a better job at shrinking the spleen.
Why this matters
Splenomegaly management in cytopenic myelofibrosis patients has been complicated by ruxolitinib’s tendency to worsen anemia and thrombocytopenia, often forcing dose reductions that limit spleen response. A direct head-to-head trial of momelotinib (which may preserve or improve cytopenias via ACVR1 inhibition) against ruxolitinib in this specific subpopulation could clarify the preferred first-line JAK inhibitor for spleen-directed symptom control when blood counts are low.